Anavex Life Sciences (AVXL) Receiving Favorable Press Coverage, Report Finds

Media headlines about Anavex Life Sciences (NASDAQ:AVXL) have been trending positive recently, according to Accern. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Anavex Life Sciences earned a news impact score of 0.28 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 44.7432694703604 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:

Shares of Anavex Life Sciences (NASDAQ:AVXL) traded down $0.16 during mid-day trading on Monday, hitting $3.58. The company had a trading volume of 281,908 shares, compared to its average volume of 405,758. Anavex Life Sciences has a one year low of $3.33 and a one year high of $6.64.

AVXL has been the topic of several research analyst reports. Zacks Investment Research upgraded Anavex Life Sciences from a “hold” rating to a “buy” rating and set a $4.75 price objective on the stock in a research note on Monday, August 28th. Maxim Group set a $15.00 target price on Anavex Life Sciences and gave the stock a “buy” rating in a research report on Monday, August 7th. Noble Financial restated a “buy” rating and set a $15.00 target price on shares of Anavex Life Sciences in a research report on Friday, September 29th. Finally, ValuEngine downgraded Anavex Life Sciences from a “hold” rating to a “sell” rating in a research report on Tuesday, November 21st.

TRADEMARK VIOLATION NOTICE: This piece was first posted by Week Herald and is owned by of Week Herald. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at https://weekherald.com/2017/12/04/anavex-life-sciences-avxl-receiving-favorable-press-coverage-report-finds.html.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.

Insider Buying and Selling by Quarter for Anavex Life Sciences (NASDAQ:AVXL)

Receive News & Ratings for Anavex Life Sciences Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences Corp. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply